

Alessandro Laganà, PhD

Department of Oncological Sciences
Department of Genetics and Genomic Sciences
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
1470 Madison Avenue, Rm 5-107
New York, NY 10029
Phone: (212) 824-8436

E-mail: alessandro.lagana@mssm.edu; alessandro.lagana@gmail.com

Research IDs: ORCID 0000-0003-1134-0564 | Scopus Author ID 55222216700 | Web of Science ID NJS-3714-2025

Academic Appointments

2021 - Present *Assistant Professor (Tenure Track)*
Department of Oncological Sciences
Department of Genetics and Genomic Sciences
Mount Sinai Tisch Cancer Center
Icahn School of Medicine at Mount Sinai, New York, NY

Role Description and current activities:

Faculty and Principal Investigator (PI) of a research team of Computational Genomics and Artificial Intelligence applied to Oncology (Laganà Lab). The research activities of the lab focus on bioinformatics, integrative cancer genomics, biology of complex systems, and precision oncology. I currently supervise two post-doctoral researchers, one PhD student, and three bioinformaticians. I am the PI of projects funded by foundations and industry, and co-Investigator in projects funded by NIH. I serve in the committees for the review of clinical trials and precision oncology. I am a training-faculty mentor in the Genetics & Genomic Sciences and Cancer Biology PhD tracks and serve as interview panel member for the PhD/MD-PhD admissions.

2017 - 2021 *Research Assistant Professor*
Department of Genetics and Genomic Sciences
Institute for Data Science and Genomic Technologies
Icahn School of Medicine at Mount Sinai, New York, NY

Research Experience

2014 – 2017 *Senior Scientist*
Joel Dudley's Lab
Department of Genetics and Genomic Sciences
Institute for Next Generation Healthcare
Icahn School of Medicine at Mount Sinai, New York, NY

2010 – 2014 *Post-Doctoral Researcher*
Carlo Croce's Lab
Department of Molecular Virology, Immunology and Medical Genetics
Comprehensive Cancer Center,
The Ohio State University, Columbus, OH

2010 *Post-Doctoral Fellow*
Alfredo Ferro's Lab
Department of Biomedical Sciences
University of Catania, Catania, Italy

Education

2009	Ph.D.	University of Catania, Catania, Italy Dissertation Advisor: Alfredo Ferro
2004	M.Sc.	University of Catania, Catania, Italy Thesis Advisor: Alfredo Ferro

Grants, Contracts and Foundation Support

2023 - 2026	MMRF Myeloma Accelerator Challenge Award: Transforming Treatment of High-Risk Myeloma (Active) Role: Principal Investigator
2022 - 2025	BMS/Celgene single-cell consortium (Active) Role: Principal Investigator
2024 – 2027	MMRF Clinical & Multi-Omics Platforms to Define High-Risk Smoldering Multiple Myeloma (Active) Role: Co-Investigator
2023 – 2025	Genentech - Immune and Genomic Profile of the Tumor Microenvironment of BCMA CAR-T cell and Bi-specific Therapy-Resistant Multiple Myeloma (Active) Role: Co-Investigator
2020 - 2025	NIH-NCI R01-1R01CA244899-01A1 (Active) Development of a multi-omic clinical decision platform to guide personalized therapy PI: Samir Parekh Role: Co-Investigator
2022 - 2023	ASH Bridge Grant A multi-omics integrative network approach for the discovery of key drivers and novel treatments of multiple myeloma Role: Principal Investigator
2017 - 2019	NCI-NIH R21-CA209875-01A1 Title: A Network-Based Approach for Personalized Treatment of Multiple Myeloma PIs: Samir Parekh, Joel Dudley Role: Key Personnel

Certifications and Professional Qualifications

2025 – 2037	Italian National Scientific Qualification (ASN), <u>Associate Professor</u> level, in: 05/I1: Genetics 05/E2: Molecular Biology 06/D3: Blood diseases, Oncology and Rheumatology 06/N1: Technology and Methodology in Medicine and Nursing Sciences
-------------	--

Committee Service

2024 - Present	Protocol Review and Monitoring System Committee (PRMC) Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, NY
----------------	---

2024 – Present Caris Precision Oncology Alliance Steering Committee
Icahn School of Medicine at Mount Sinai, New York, NY

Scholarly Activities

Editorial Boards

2025 - Present *Associate Editor*: Journal of Precision Health

2017 - Present *Review Editor* in Precision Medicine and Bioinformatics and Artificial Intelligence for Molecular Medicine – Frontiers journals

2015 - Present *Associate Editor*: Frontiers in Computational Genomics

Editing of Books and Special Research Topics

2022 *Editor*: Computational Methods for Precision Oncology (Springer Advances in Experimental Medicine and Biology Series) ISBN: 978-3-030-91836-1.

2019 *Editor*: MicroRNA Target Identification: Methods and Protocols (Springer Protocols - Methods in Molecular Biology Series) ISBN-13: 978-1493992065. ISBN-10: 1493992066.

2015 *Editor*: Research Topic: Bioinformatics of Non-Coding RNAs with Applications to Biomedicine: Recent Advances and Open Challenges – Frontiers in Bioengineering and Biotechnology (Co-edited with Carlo Croce and Alfredo Ferro)

Reviewing Activity

2010 - Present Reviewer for the following journals: Bioinformatics, Biomedicine & Pharmacotherapy, Blood, Blood Advances, BMC Medicine, Briefings in Bioinformatics, Chromosome Research, Clinical Cancer Research, FEBS, Frontiers in Medicine, Frontiers in Genetics, Frontiers in Immunology, Frontiers in Neurology, Frontiers in Oncology, GigaByte, GigaScience, Haematologica, Hematology, Journal of Computational Science, Med, Nature, Nature Communications, Nucleic Acids Research, Oncogene, The Oncologist, Personalized Medicine, PLoS ONE, Scientific Reports.

Conference Organization

2009 Member of the organizing committee: *NETTAB 2009 Ninth Annual Workshop on "Network Tools and Applications in Biology"*, University of Catania, Department of Mathematics and Computer Science, June 10-12 2009.

Professional Memberships

2022 – Present Member of the American Society of Hematology (ASH).

2022 – Present Faculty Member of the International Myeloma Society (IMS).

Teaching and Mentoring Activities

2025 Lead lecturer, PhD short course "Multi-Omics Patient Stratification" (Hybrid format) (12 hours).
Course director: Prof. Rosalba Giugno.
PhD in Computer Science. University of Verona, Italy.

2024 Supervisor of a MSc Biomedical Sciences dissertation (Icahn School of Medicine at Mount Sinai).

2024	External co-advisor of a PhD student in “Sistemi Complessi per le scienze fisiche, socio-economiche e della vita”. University of Catania, Italy.
2024	External capstone PI, Masters of “Information Systems Management” & “Healthcare Analytics & Information Technology”, Carnegie Mellon University, Pittsburgh, USA.
2024	Lecturer, PhD short course “Multi-omics Data Analysis and Integration for Precision Oncology” (Virtual) (6 hours). Course director: Prof. Rosalba Giugno. PhD in Computer Science. University of Verona, Italy.
2020-2024	External Reviewer of 3 PhD theses for the Phd Program “Sistemi Complessi per le scienze fisiche, socio-economiche e della vita”. University of Catania, Italy.
2025 – Present	Advisor of 1 PhD student on translational cancer biology (Ovarian Cancer) (Icahn School of Medicine at Mount Sinai).
2022 – Present	Co-advisor of 2 completed PhD theses on translational cancer biology (Myeloma) (Icahn School of Medicine at Mount Sinai).
2022 – Present	Interview panel member, PhD/MD-PhD admissions (Icahn School of Medicine at Mount Sinai).
2022 – Present	Training-faculty mentor, Genetics & Genomic Sciences and Cancer Biology PhD tracks (Icahn School of Medicine at Mount Sinai).
2018	J.T. Schwartz International School (Lipari, Italy): Lecture: “Precision Medicine for Multiple Myeloma”.
2004 - 2010	Co-advisor for over 30 Master's and Bachelor's theses in Computer Science. University of Catania, Italy.
2004 - 2010	Lecturer & examiner, courses “Introduction to Bioinformatics” and “Bioinformatics”. Courses director: Prof. Alfredo Ferro. Bachelor's Degree and Master's Degree Programs in Computer Science. University of Catania, Italy.
2007 - 2008	Lecturer & examiner, course “Biological Basis of Bioinformatics”. Courses director: Prof. Alfredo Ferro. Master's Degree Program in Computer Science. University of Catania, Italy.

Invited Lectures

18/08/2025	2nd Annual MMRF AI/ML Workshop (Multiple Myeloma Research Foundation) (Virtual Seminar): “AI Approaches in Precision Medicine of Multiple Myeloma”.
16/07/2025	Lipari International School on Computational Life Sciences. Title of the seminar: “Computational modeling of Multiple Myeloma: from disease subtypes to novel biological insights and precision medicine”.
12/07/2025	IMS 3rd Annual Workshop on Genomics (International Myeloma Society). Lisbon, Portugal. Title of the seminar: “Single-cell profiling and multiscale integration for risk stratification and disease subtyping in myeloma”.
24/04/2025	Sanofi Multiple Myeloma Speaker Series 2025 (virtual seminar): “Artificial Intelligence (AI) in Precision Medicine of Multiple Myeloma”.
11/04/2025	University of Verona, Italy. Computer Science Departmental Seminar Series: “Computational Modeling in Multiple Myeloma: Multi-omics Integration, Generative AI, and the Road to Precision Oncology”.

29/01/2025	University of Oxford, United Kingdom. 5th Oxford Myeloma Workshop: satellite workshop on <i>Emerging single-cell and spatial technologies to dissect the bone marrow myeloma environment</i> . "Multimodal Single-Cell Assay".
04/12/2024	MMRF Immunity Workshop (San Diego, CA): "AI/ML approaches for precision medicine and myeloma research".
02/08/2024	Inaugural MMRF AI/ML Workshop (Virtual event): "Towards AI-enhanced precision medicine of multiple myeloma".
12/07/2024	IMS Genomics and Translational Medicine in Myeloma (Barcelona, Spain): "Role of High-Risk Genomic Events in Multiple Myeloma Patients Treated with Venetoclax".
20/10/2023	University of Oxford, United Kingdom. 4th Oxford Myeloma Workshop. "Clinical applications of single-cell technologies".
15/06/2023	University of Catania, Italy. Virtual Seminar: "Computational modeling of Multiple Myeloma: from disease subtypes to novel biological insights and precision medicine".
19/03/2021	University of Sussex, Brighton, United Kingdom. Biochemistry and Biomedicine seminar series (Virtual seminar): "Computational modeling of Multiple Myeloma: from disease subtypes to novel biological insights".
16/10/2020	City of Hope, Duarte, CA. Briskin Meeting Presentation (Virtual seminar): "Patient Similarity Network of Multiple Myeloma Identifies Patient Subgroups with Distinct Genetic Features and Clinical Implications".
03/12/2019	The New York Academy of Sciences, New York, NY. Symposium <i>"Enabling Technology and Data for Drug Repositioning"</i> . Lecture: "Precision Medicine of Multiple Myeloma Based on an Integrative Multi-omics Approach".

Selected Oral Presentations at International Conferences

01/12/2018	American Society of Hematology (ASH) 2018 (San Diego, California, USA): "Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma".
09/12/2017	American Society of Hematology (ASH) 2017 (Atlanta, Georgia, USA): "Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Followup Study from the MMRF Compass Genomics Project".
09/12/2017	American Society of Hematology (ASH) 2017 (Atlanta, Georgia, USA): "ADAR-Mediated Aberrant A-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma".
03/12/2016	American Society of Hematology (ASH) 2016 (San Diego, California, USA): "Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification".
05/12/2015	American Society of Hematology (ASH) 2015 (Orlando, Florida, USA): "Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma".
01/04/2010	Bioinformatics Italian Society (BITS) 2010 (Bari): "The miRò project: towards a unified resource for miRNA research".
26/04/2007	Bioinformatics Italian Society (BITS) 2007 (Napoli): "Prediction of human targets for viral encoded microRNAs by thermodynamics and empirical constraints".

Publications

Peer-reviewed journals

62. D. J. Ohlstrom, W. C. Pilcher, M. E. Michaud, C. Acharya, S. Satpathy, E. Gonzalez-Kozlova, R. G. Jayasinghe, K. Ferguson, H. L. Mumme, S. Nanda, Y. Song, S. Mantrala, D. Karagkouni, J. Schulman, N. Pabustan, J. Vieira Dos Santos, D. W. Sherbenou, J.

- J. Keats, A. M. Gout, S. Foltz, **A. Laganà**, T. Kourelis, R. Vij, M. V. Dhodapkar, D. Avigan, H. J. Cho, L. B. Baughn, A. K. Nooka, S. Lonial, S. Kumar, M. K. Samur, I. S. Vlachos, L. Ding, S. Gnjatic, G. Mulligan, M. Bhasin. Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma. Accepted in *Blood Cancer Discovery* 2025.
61. W.C. Pilcher, L. Yao, E. Gonzalez-Kozlova, Y. Pita-Juarez, D. Karagkouni, C. R. Acharya, M. E. Michaud, M. Hamilton, S. Nanda, Y. Song, K. Sato, J. T. Wang, S. Satpathy, Y. Ma, J. Schulman, D. D'Souza, R. G. Jayasinghe, G. Cheloni, M. Bakhtiari, N. Pabustan, K. Nie, J. A. Foltz, I. Saldarriaga, R. Alaaeldin, E. Lepisto, R. Chen, M. A. Fiala, B. E Thomas, A. Cook, J. Vieira Dos Santos, I. Chiang, I. Figueiredo, J. Fortier, M. Slade, S. T. Oh, M. P. Rettig, E. Anderson, Y. Li, S. Dasari, M. A Strausbauch, V. A Simon, Immune Atlas Consortium, A. H. Rahman, Z. Chen, **A. Laganà**, J. F. DiPersio, J. Rosenblatt, S. Kim-Schulze, M. V. Dhodapkar, S. Lonial, S. Kumar, S. S. Bhasin, T. Kourelis, R. Vij, D. Avigan, H. J. Cho, G. Mulligan, L. Ding, S. Gnjatic, I. S. Vlachos, M. Bhasin. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma. To appear in *Nature Cancer* 2025.
 60. J. Vieira Dos Santos, D. T. Melnekoff, A. Aleman, T. H. Mouhieddine, R. Montes de Oca, F. Wang, S. Rajeeve, S. Bhalla, O. Van Oekelen, B. Upadhyaya, Y. Ghodke-Puranik, V. Leshchenko, S. Kim-Schulze, A. H. Rahman, S. Afik, H. Lewinsky, V. Plaks, S. Thibaud, H. J. Cho, J. Richter, C. Rodriguez, L. J. Sanchez, A. C. Rossi, S. Richard, A. Chari, D. Madduri, S. Jagannath, S. Parekh, **A. Laganà**. Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression. *Blood Advances* 2025; Nov 5: bloodadvances.2025018078. doi: 10.1182/bloodadvances.2025018078.
 59. A. Aleman, O. Van Oekelen, D. T. Melnekoff, L. Grossman, T. Mouhieddine, A. Kurowski, I. Odak, S. Reci, S. Desai, S. Meledathu, M. P. Naidu, R. P. Shukla, R. P. Dutta, K. Kappes, K. Serebryakova, H. Jackson, J. Lu, A. Chatikhine, R. Kulkarni, Z. Moinfar, M. M. Croken, M. Mehrotra, B. Baskovich, S. Rayamajhi, S. Richard, A. C. Rossi, C. Salib, J. Houldsworth, B. D. Brown, M. Merad, **A. Laganà**, P. M. Brunner, S. Jagannath, J. D. Brody, S. Parekh. Personalized Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR-T. *New England Journal of Medicine* 2025; 393(8):823-825. doi: 10.1056/NEJMc2504588.
 58. M. Ram M, M. R. Fraser, J. Vieira Dos Santos, R. Tasakis, A. Islam, J. U. Abo-Donia, S. Parekh, **A. Laganà**. The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward. *Pharm Genomics Pers Med* 2024 Dec 21; 17:573-609. doi: 10.2147/PGPM.S350238. eCollection 2024.
 57. R. P. Dutta, S. Thibaud, V. Leshchenko, M. Ram, D. T. Melnekoff, S. Bhalla, P. Restrepo, V. A. Gupta, B. G. Barwick, S. Newman, J. McCafferty, F. Hantash, A. K. Nooka, H. J. Cho, S. Richard, C. Rodriguez, A. Rossi, L. Sanchez, A. Chari, L. H. Boise, S. Jagannath, J. Richter, S. Parekh, **A. Laganà**. Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. *Blood Neoplasia* 2024; 1 (4): 100049. doi: <https://doi.org/10.1016/j.bneo.2024.100049>.
 56. S. Bodnar, T. Brander, J. Gold, A. Iverson, **A. Laganà**, K. Onel, S. Jagannath, S. Parekh, S. Thibaud. FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk. *Semin Hematol* 2024 Nov 30: S0037-1963(24)00131-8. doi: 10.1053/j.seminhematol.2024.11.006.
 55. A. H. Mei, **A. Laganà**, R. Osman, H. J. Cho. Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma. *Semin Hematol* 2024 Oct 28: S0037-1963(24)00124-0. doi:10.1053/j.seminhematol.2024.10.007.
 54. Z. M. Avigan, C. S. Mitsiades, **A. Laganà**. The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges. *Semin Hematol* 2024; Oct 5: S0037-1963(24)00111-2. doi: 10.1053/j.seminhematol.2024.10.001.
 53. S. Thibaud, R. L. Subaran, S. Newman, **A. Laganà**, D. T. Melnekoff, S. Bodnar, M. Ram, Z. Soens, W. Genthe, T. Brander, T. H. Mouhieddine, O. Van Oekelen, J. Houldsworth, H. J. Cho, S. Richard, J. Richter, C. Rodriguez, A. Rossi, L. Sanchez, A. Chari, E. Moshier, S. Jagannath, S. Parekh, K. Onel. Multiple Myeloma Risk and Outcomes are Associated with Pathogenic Germline Variants in DNA Repair Genes. *Blood Cancer Discov* 2024; 5 (6): 428–441. doi: 10.1158/2643-3230.BCD-23-0208.
 52. O. Van Oekelen, M. Amatangelo, M. Guo, B. Upadhyaya, A. P. Cribbs, G. Kelly, M. Patel, S. Kim-Schulze, E. Flynt, **A. Laganà**, S. Gooding, M. Merad, S. Jagannath, W. E. Pierceall, U. Oppermann, A. Thakurta, S. Parekh. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma. *Cell Rep Med* 2024 Jun 18;5(6):101584. doi:10.1016/j.xcrm.2024.101584.
 51. T. H. Mouhieddine, O. Van Oekelen, D. T. Melnekoff, J. Li, Y. Ghodke-Puranik, G. Lancman, S. Thibaud, D. Pan, S. Rajeeve, S. Agte, A. Aleman, L. Sanchez, S. Richard, A. Rossi, J. Richter, H. J. Cho, C. Rodriguez, **A. Laganà**, E. L. Moshier, A. Chari, S. Jagannath, S. Parekh. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. *Blood Adv.* 2023; 7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923.
 50. R. Distefano, L. Tomasello, G. L. Rampioni Vinciguerra, P. Gasparini, Y. Xiang, M. Bagnoli, G. P. Marceca, P. Fadda, **A. Laganà**, M. Acunzo, Q. Ma, G. Nigita, C. M. Croce. Pan-Cancer Analysis of Canonical and Modified miRNAs Enhances the Resolution of the Functional miRNAome in Cancer. *Cancer Res.* 2022; 82(20): 3687–3700.

49. M. Elnaggar, S. Agte, P. Restrepo, M. Ram, D. Melnekoff, C. Adamopoulos, M. M. Stevens, K. Kappes, V. Leshchenko, D. Verina, S. Jagannath, P. I. Poulikakos, S. Parekh, **A. Laganà**. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. *J Hematol Oncol.* 2022; 15(1):109. doi: 10.1186/s13045-022-01330-3.
48. P. Restrepo, S. Bhalla, Y. Ghodke-Puranik, A. Aleman, V. Leshchenko, D. T. Melnekoff, S. Agte, J. Jiang, D. Madduri, J. Richter, S. Richard, A. Chari, H. J. Cho, S. Jagannath, C. J. Walker, Y. Landesman, **A. Laganà**, S. Parekh. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. *JCO Precis Oncol.* 2022; 6:e2200147. doi: 10.1200/PO.22.00147.
47. O. Van Oekelen, A. Aleman, B. Upadhyaya, S. Schnakenberg, D. Madduri, S. Gavane, J. Teruya-Feldstein, J. F. Cray, M. E. Fowkes, C. B. Stacy, S. Kim-Schulze, A. Rahman, **A. Laganà**, J. D. Brody, M. Merad, S. Jagannath, S. Parekh. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. *Nature Medicine* 2021; <https://doi.org/10.1038/s41591-021-01564-7>.
46. S. Bhalla, D. T. Melnekoff, A. Aleman, V. Leshchenko, P. Restrepo, J. Keats, K. Onel, J. R. Sawyer, D. Madduri, J. Richter, S. Richard, A. Chari, H. J. Cho, J. T. Dudley, S. Jagannath, **A. Laganà**, S. Parekh. Patient Similarity Network of Multiple Myeloma identifies patient sub-groups with distinct genetic and clinical features. *Science Advances* 2021; 7(47). doi:10.1126/sciadv.abg9551.
45. S. S. Jatiani, S. Christie, V. V. Leshchenko, R. Jain, A. Kapoor, P. Bisignano, C. Lee, H. Ü. Kaniskan, D. Edwards, F. Meng, **A. Laganà**, Y. Youssef, A. Wiestner, L. Alinari, J. Jin, M. Filizola, A. K. Aggarwal, S. Parekh. SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma. *Clin Cancer Res* 2021; 27(16):4652-4663. doi: 10.1158/1078-0432.CCR-20-5039.
44. G. P. Marceca, R. Distefano, L. Tomasello, **A. Laganà**, F. Russo, F. Calore, G. Romano, M. Bagnoli, P. Gasparini, A. Ferro, M. Acunzo, Q. Ma, C. M. Croce, G. Nigita. MIREDiBase, a manually curated database of validated and putative editing events in microRNAs. *Scientific Data* 2021; 8:199. doi: <https://doi.org/10.1038/s41597-021-00979-8>.
43. A. Chari, E. Florendo, I. S. Mancina, H. Cho, D. Madduri, S. Parekh, J. Richter, A. Dhadwal, J. Thomas, G. Jiang, **A. Laganà**, S. Bhalla, S. Jagannath. Optimal Supportive Care with Selinexor Improves Outcomes in Patients with Relapsed/Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma & Leukemia* 2021; doi: <https://doi.org/10.1016/j.clml.2021.07.014>.
42. R. Upadhyay, J. A. Boiarsky, G. Pantsulaia, J. Svensson-Arvelund, M. J. Lin, A. Wroblewska, S. Bhalla, N. Scholler, A. Bot, J. M. Rossi, N. Sadek, S. Parekh, **A. Laganà**, A. Baccarini, M. Merad, B. D. Brown, J. D. Brody. A critical role for fas-mediated off-target tumor killing in T cell immunotherapy. *Cancer Discovery* 2020; doi: 10.1158/2159-8290.CD-20-0756.
41. M. R. Sapienza, F. Fuligni, F. Melle, V. Tabanelli, V. Indio, M. A. Laginestra, G. Motta, S. Mazzara, L. Cerroni, A. Pileri, F. Facchetti, M. Paulli, L. Cascione, **A. Laganà**, E. Berti, C. Agostinelli, E. Sabattini, C. M. Croce, S. A. Pileri. MicroRNA profiling of Blastic Plasmacytoid Dendritic Cell Neoplasm and Myeloid Sarcoma. *Hematological Oncology* 2020; doi: <https://doi.org/10.1002/hon.2782>.
40. O. Van Oekelen, S. Parekh, H. J. Cho, N. Vishnuvardhan, D. Madduri, J. Richter, C. Ip, K. Lau, E. Florendo, I. S. Mancina, J. Thomas, D. Verina, E. Chan, K. Zarychta, L. La, G. Strumolo, D. T. Melnekoff, V. V. Leshchenko, S. Kim-Schulze, S. Cuoto, M. Wang, W. E. Pierceall, A. Thakurta, **A. Laganà**, S. Jagannath, A. Chari. A Phase II Study of Pomalidomide, Daily Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. *Leukemia & Lymphoma* 2020; doi: 10.1080/10428194.2020.1805111.
39. A. Ma, E. Stratikopoulos, K.S. Park, J. Wei, T. C. Martin, X. Yang, M. Schwarz, V. Leshchenko, A. Rialdi, B. Dale, **A. Laganà**, E. Guccione, S. Parekh, R. Parsons, J. Jin. Discovery of a first-in-class EZH2 selective degrader. *Nature Chemical Biology* 2020; 16(2):214-222. doi: 10.1038/s41589-019-0421-4,
38. D. Perumal, N. Imai, **A. Laganà**, J. P. Finnigan, D. T. Melnekoff, V. Leshchenko, A. Solovyov, D. Madduri, S. Kim-Schulze, A. Chari, H. J. Cho, J. T. Dudley, J. Brody, B. Barlogie, S. Jagannath, B. Greenbaum, S. Gnjjatic, N. Bhardwaj, S. Parekh. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. *Clinical Cancer Research* 2019; 26(2):450-464. doi: 10.1158/1078-0432.CCR-19-2309.
37. Y. Liu, H. Yu, S. Yoo, E. Lee, **A. Laganà**, S. Parekh, E. E. Schadt, L. Wang, J. Zhu. A Network Analysis of Multiple Myeloma Related Gene Signatures. *Cancers (Basel)* 2019; 11(10). pii: E1452. doi: 10.3390/cancers11101452.
36. **A. Laganà**, I. Beno, T. D. Melnekoff, V. Leshchenko, D. Madduri, D. Ramdas, L. Sanchez, S. Niglio, D. Perumal, B. A. Kidd, R. Miotto, J. Houldsworth, R. Shaknovich, A. Chari, H. J. Cho, B. Barlogie, S. Jagannath, J. T. Dudley, S. Parekh. Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. *JCO Precis Oncol* 2018; doi: 10.1200/PO.18.00019.

35. L. Shi, J. Middleton, Y. J. Jeon, P. Magee, D. Veneziano, **A. Laganà**, H. S. Leong, S. Sahoo, M. Fassan, R. Booton, R. Shah, P. A. J. Crosbie, M. Garofalo. KRAS induces lung tumorigenesis through microRNAs modulation. *Cell Death Dis* 2018; 13(9):219. doi: 10.1038/s41419-017-0243-9.
34. **A. Laganà**, D. Perumal, D. Melnekoff, B. Readhead, B. Kidd, V. Leshchenko, P. Y. Kuo, J. Keats, M. DeRome, J. Yesil, D. Auclair, S. Lonial, A. Chari, H. J. Cho, B. Barlogie, S. Jagannath, J. T. Dudley, S. Parekh. Integrative Network Analysis Identifies Novel Drivers of Pathogenesis and Progression in Newly Diagnosed Multiple Myeloma. *Leukemia* 2018; 32(1):120-130. doi: 10.1038/leu.2017.197.
33. S. Naidu, L. Shi, P. Magee, J. D. Middleton, **A. Laganà**, S. Sahoo, H. S. Leong, M. Galvin, K. Frese, C. Dive, V. Guzzardo, M. Fassan, M. Garofalo. PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF- κ B pathways. *Scientific Reports* 2017; doi:10.1038/s41598-017-14843-6.
32. F. Russo, S. Di Bella, F. Vannini, G. Berti, F. Scoyni, H. V. Cook, A. Santos, G. Nigita, V. Bonnici, **A. Laganà**, F. Geraci, A. Pulvirenti, R. Giugno, F. De Masi, K. Belling, L. J. Jensen, S. Brunak, M. Pellegrini, A. Ferro. miRandola 2017: a curated knowledge base of non-invasive biomarkers. *Nucleic Acids Res* 2017; gkx854, <https://doi.org/10.1093/nar/gkx854>.
31. A. Chari, H. J. Cho, A. Dhadwal, G. Morgan, L. La, K. Zarychta, D. Catamero, E. Florendo, N. Stevens, D. Verina, E. Chan, V. Leshchenko, **A. Laganà**, D. Perumal, A. H. Mei, K. Tung, J. Fukui, S. Jagannath, S. Parekh. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. *Blood Adv* 2017; 1(19):1575-1583. doi: 10.1182/bloodadvances.2017007427.
30. **A. Laganà**, W. P. Dirksen, W. Supsavhad, A. S. Yilmaz, H. G. Ozer, J. D. Feller, K. A. Vala, C. M. Croce, T. J. Rosol. Discovery and characterization of the feline miRNAome. *Scientific Reports* 2017; doi:10.1038/s41598-017-10164-w.
29. M. Acunzo, G. Romano, G. Nigita, D. Veneziano, L. Fattore, **A. Laganà**, N. Zanesi, P. Fadda, M. Fassan, L. Rizzotto, R. Kladney, V. Coppola, C. M. Croce. Selective targeting of point-mutated KRAS through artificial microRNAs. *Proc Natl Acad Sci U S A* 2017; doi: 10.1073/pnas.1620562114.
28. D. Veneziano, S. Di Bella, G. Nigita, **A. Laganà**, A. Ferro, C. M. Croce. Non-coding RNA: Current Deep Sequencing Data Analysis Approaches and Challenges. *Human Mutation* 2016; 37 (12) 1283-1298.
27. L. Fattore, R. Mancini, M. Acunzo, G. Romano, **A. Laganà**, M. E. Pisanue, D. Malpiccie, G. Madonna, D. Mallardo, M. Capone, F. Fulciniti, L. Mazzucchelli, G. Botti, C. M. Croce, P. A. Ascierto, G. Ciliberto. miR-579-3p controls melanoma progression and resistance to target therapy. *Proc Natl Acad Sci U S A* 2016; 113(34):E5005-13. doi: 10.1073/pnas.1607753113.
26. G. Nigita, M. Acunzo, G. Romano, D. Veneziano, **A. Laganà**, M. Vitiello, D. Wernicke, A. Ferro, C. M. Croce. microRNA editing in seed region aligns with cellular changes in hypoxic conditions. *Nucleic Acids Res* 2016; 44(13):6298-308. doi: 10.1093/nar/gkw532.
25. **A. Laganà**, D. Veneziano, T. Spata, R. Tang, H. Zhu, P. J. Mohler, A. Kilic. Identification of General and Heart-Specific miRNAs in Sheep (*Ovis aries*). *PLoS ONE* 2015; doi: 10.1371/journal.pone.0143313.
24. E. Tili, M. Chiabai, D. Palmieri, M. Brown, R. Cui, C. Fernandes, T. Richmond, T. Kim, T. Sheetz, H. L. Sun, **A. Laganà**, D. Veneziano, S. Volinia, L. Rassenti, T. Kipps, H. Awad, J. J. Michaille, C. M. Croce. Quaking and miR-155 interactions in inflammation and leukemogenesis. *Oncotarget* 2015; 6(28):24599-610.
23. P. Joshi P, Y. J. Jeon, **A. Laganà**, J. Middleton, P. Secchiero, M. Garofalo, C. M. Croce. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. *Proc Natl Acad Sci U S A* 2015; 112(28):8650-5.
22. Y. J. Jeon, J. Middleton, T. Kim, **A. Laganà**, C. Piovani, P. Secchiero, G. J. Nuovo, R. Cui, P. Joshi, G. Romano, G. Di Leva, B. K. Lee, H. L. Sun, Y. Kim, P. Fadda, H. Alder, M. Garofalo, C. M. Croce. A set of NF- κ B-regulated microRNAs induces acquired TRAIL resistance in Lung cancer. *Proc Natl Acad Sci U S A* 2015; 112(26):E3355-64.
21. A. Drusco, A. Bottoni, **A. Laganà**, M. Acunzo, M. Fassan, L. Cascione, A. Antenucci, P. Kumchala, C. Vicentini, M. P. Gardinam, H. Alder, M. A. Carosi, M. Ammirati, S. Gherardi, M. Luscri, C. Carapella, N. Zanesi, C. M. Croce. A differentially expressed set of micrornas in cerebrospinal fluid (CSF) can diagnose CNS malignancies. *Oncotarget* 2015; 6(25):20829-39.
20. S. V. Thomas, **A. Laganà**, K. M. Dittmar, P. E. Wakely Jr. Imprint cytopathology of core needle biopsies: a first responder role for cytotechnologists. *Journal of the American Society of Cytopathology* 2014; 4(1): 16-24.
19. A. Efanov, N. Zanesi, V. Coppola, G. Nuovo, B. Bolon, D. Wernicke-Jameson, **A. Laganà**, H. Alder, F. Pichiorri and C. M. Croce. Human HMGA2 protein overexpressed in mice induces precursor T-cell lymphoblastic leukemia. *Blood Cancer J* 2014; 4:e227.
18. F. Russo, S. Di Bella, V. Bonnici, **A. Laganà**, G. Rainaldi, M. Pellegrini, A. Pulvirenti, R. Giugno, A. Ferro. A knowledge base for the discovery of function, diagnostic potential and drug effects on cellular and extracellular miRNAs. *BMC Genomics* 2014; 15(Suppl 3):S4.

17. **A. Laganà**, M. Acunzo, G. Romano, A. Pulvirenti, D. Veneziano, L. Cascione, R. Giugno, P. Gasparini, D. Shasha, A. Ferro, C. M. Croce. miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. *Nucleic Acids Res* 2014; 42(9):5416-5425.
16. P. Nasarre, R. M. Gemmill, V. A. Potiron, J. Roche, X. Lu, A. E. Baron, C. Korch, E. Garrett-Mayer, **A. Laganà**, P. H. Howe, H. A. Drabkin. Neuropilin-2 is upregulated in lung cancer cells during TGF1-induced epithelialmesenchymal transition. *Cancer Res* 2013; 73(23):7111-7121.
15. M. Acunzo, G. Romano, D. Palmieri, **A. Laganà**, M. Garofalo, V. Balatti, A. Drusco, M. Chiariello, P. Nana-Sinkam, C. M. Croce. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. *Proc Natl Acad Sci U S A* 2013; 110(21):8573-8578.
14. F. Pichiorri, D. Palmieri, L. De Luca, J. Consiglio, J. You, A. Rocci, T. Talabere, C. Piovan, **A. Laganà**, L. Cascione, J. Guan, P. Gasparini, V. Balatti, G. Nuovo, V. Coppola, C. C. Hofmeister, G. Marcucci, J. C. Byrd, S. Volinia, C. L. Shapiro, M. A. Freitas, C. M. Croce. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. *J Exp Med* 2013; 210(5):951-68.
13. N. Zanesi, V. Balatti, J. Riordan, A. Burch, L. Rizzotto, A. Palamarchuk, L. Cascione, **A. Laganà**, A. J. Dupuy, C. M. Croce, Y. Pekarsky. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model. *Blood* 2013; 121(21):4355-4358.
12. V. Manfe, E. Biskup, A. Willumsgaard, A. G. Skov, D. Palmieri, P. Gasparini, **A. Laganà**, A. Woetmann, N. Odum, C. M. Croce, R. Gniadecki. cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. *PLoS ONE* 2013; 8(3): e59390.
11. R. Distefano, G. Nigita, V. Macca, **A. Laganà**, R. Giugno, A. Pulvirenti, A. Ferro. VIRGO: visualization of A-to-I RNA editing sites in genomic sequences. *BMC Bioinformatics* 2013; 14(Suppl 7): S5.
10. F. Russo, S. Di Bella, G. Nigita, V. Macca, **A. Laganà**, R. Giugno, A. Pulvirenti, A. Ferro. miRandola: Extracellular Circulating MicroRNAs Database. *PLoS ONE* 2012; 7(10): e47786.
9. **A. Laganà**, A. Paone, D. Veneziano, L. Cascione, P. Gasparini, S. Carasi, F. Russo, G. Nigita, V. Macca, R. Giugno, A. Pulvirenti, D. Shasha, A. Ferro, C. M. Croce. miR-EdiTar: A database of predicted A-to-I edited miRNA target sites. *Bioinformatics* 2012; 28(23): 3166-3168.
8. P. Ranganathan, C. E. Heaphy, S. Costinean, N. Stauffer, C. Na, M. Hamadani, R. Santhanam, C. Mao, P. A. Taylor, S. Sandhu, G. He, A. Shana'ah, G. J. Nuovo, **A. Laganà**, L. Cascione, S. Obad, O. Broom, S. Kauppinen, J. C. Byrd, M. Caligiuri, D. Perrotti, G. A. Hadley, G. Marcucci, S. M. Devine, B. R. Blazar, C. M. Croce, R. Garzon. Regulation of acute graft-versus-host disease by microRNA-155. *Blood* 2012; 119(20): 4786-4797.
7. **A. Laganà**, F. Russo, C. Sismeiro, R. Giugno, A. Pulvirenti, A. Ferro. Variability in the Incidence of miRNAs and Genes in Fragile Sites and the Role of Repeats and CpG Islands in the Distribution of Genetic Material. *PLoS ONE* 2010; 5(6): e11166.
6. **A. Laganà**, S. Forte, F. Russo, R. Giugno, A. Pulvirenti, A. Ferro. Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints. *Journal of RNAi and Gene Silencing* 2010; 6(1): 379-385.
5. **A. Laganà**, S. Forte, A. Giudice, M. R. Arena, P. L. Puglisi, R. Giugno, A. Pulvirenti, D. Shasha, A. Ferro. miRo': a miRNA knowledge base. *Database* (Oxford) 2009; Vol. 2009, bap008.
4. V. Svicher, C. Alteri, R. D'Arrigo, **A. Laganà**, M. Trignetti, S. Lo Caputo, A. P. Callegaro, F. Mag- giolo, F. Mazzotta, A. Ferro, S. Dimonte, S. Aquaro, G. di Perri, S. Bonora, C. Tommasi, M. P. Trotta, P. Narciso, A. Antinori, C. F. Perno, F. Ceccherini-Silberstein. The Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the HIV-1 Regulatory Protein Rev. *Antimicrobial Agents and Chemotherapy* 2009; 53(7): 2816-2823.
3. C. Di Pietro, M. Ragusa, D. Barbagallo, L. R. Duro, M. R. Guglielmino, A. Majorana V. Giunta, A. Rapisarda, E. Tricarichi, M. Miceli, R. Angelica, A. Grillo, B. Banelli, I. DeClerari, S. Forte, **A. Laganà**, C. Bosco, R. Giugno, A. Pulvirenti, A. Ferro, K. H. Grzeschik, A. Di Cataldo, G. P. Tonini, M. Romani, M. Purrello. Involvement of GTA protein NC2beta in Neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferation. *Molecular Cancer* 2008; 7:52.
2. S. Forte, S. Scarpulla, **A. Laganà**, L. Memeo, M. Gulisano. Gene Expression Analysis for the Identification of Genes Involved in Early Tumour Development. *Proceedings of the 15th International Workshops on Conceptual Structures ICCS 2007*. Sheffield Hallam University, Sheffield UK, July 22-27, 2007; 62- 68. Ed. Springer-Verlag.
1. C. Di Pietro, M. Ragusa, L. Duro, M. R. Guglielmino, D. Barbagallo, A. Carnemolla, **A. Laganà**, P. Buffa, R. Angelica, A. Rinaldi, M. S. Calafato, I. Milicia, C. Caserta, R. Giugno, A. Pulvirenti, V. Giunta, A. Rapisarda, V. Di Pietro, A. Grillo, A. Messina, A. Ferro, K. H. Grzeschik, M. Purrello. Genomics, Evolution and Expression of TBPL2, a Member of the TBP Family. *DNA and Cell Biology* 2007; 26(6): 369-385.

Editorials and Commentaries

7. C. Henschke, D. Yankelevitz, J. W. Sidhom, M. Galsky, J. Llovet, G. Campanella, A. Schlessinger, **A. Laganà**, S. Parekh, C. Smith, K. Huang, E. Guccione, E. E. Schadt, R. Advancing cancer research with artificial intelligence. In "Frontiers of Medical Research: Artificial Intelligence". Sponsored supplement to *Science*. 11/2023.
6. **A. Laganà**. The genome of IMiD-refractory myeloma. *Blood* 2023. 141(6): 560–561. <https://doi.org/10.1182/blood.2022018461>.
5. **A. Laganà**, A. Chari, L. Isola, H. J. Cho, S. Jagannath, S. Parekh. The complexity of multiple myeloma: From pathogenesis to therapeutic alternatives. In "Frontiers of Medical Research: Cancer". Sponsored supplement to *Science*. 11/2022.
4. **A. Laganà**, S. Parekh. (Distinct) origins of IgM myeloma. *Blood* 2021. 138(20): 1914–1915. doi: <https://doi.org/10.1182/blood.2021013860>.
3. C. Tibaldi, A. D'Incecco, **A. Laganà**. MicroRNAs and Targeted Therapies in Non-Small Cell Lung Cancer: Minireview. *Anticancer Agents Med Chem* 2015; 15(6):694-700.
2. **A. Laganà**, A. Ferro, C. M. Croce. Bioinformatics of Non-Coding RNAs with Applications to Biomedicine: Recent Advances and Open Challenges. *Front Bioeng Biotechnol* 2015; 3:156. doi: 10.3389/fbioe.2015.00156.
1. **A. Laganà**, D. Shasha, C. M. Croce. Synthetic RNAs for gene regulation: design principles and computational tools. *Front Bioeng Biotechnol* 2014; 2:65. doi: 10.3389/fbioe.2014.00065.

Book chapters

12. **A. Laganà**, S. Sariya, D. T. Melnekoff, M. Ram, S. Parekh. Utilizing RADAR for the Integration of Genomic Data and Immunotherapy Targets in Precision Oncology for Multiple Myeloma. *Cancer Detection and Diagnosis: A Handbook of Emerging Technologies*, 2025; 280-294.
11. **A. Laganà**. The search for cancer drivers. *From Computational Logic to Computational Biology*, Lecture Notes in Computer Science 2024; 14070, 145–171.
10. O. Van Oekelen, **A. Laganà**. Multi-Omics Profiling of the Tumor Microenvironment. *Adv Exp Med Biol*. 2022; 1361:283-326
9. D.T. Melnekoff, **A. Laganà**. Single-Cell Sequencing Technologies in Precision Oncology. *Adv Exp Med Biol*. 2022; 1361:269-282.
8. S. Bhalla, **A. Laganà**. Artificial Intelligence for Precision Oncology. *Adv Exp Med Biol*. 2022; 1361:249-268.
7. **A. Laganà**. Computational Approaches for the Investigation of Intra-tumor Heterogeneity and Clonal Evolution from Bulk Sequencing Data in Precision Oncology Applications. *Adv Exp Med Biol*. 2022;1361:101-118.
6. W. Osman, **A. Laganà**. Software Workflows and Infrastructures for Precision Oncology. *Adv Exp Med Biol*. 2022; 1361:23-35.
5. **A. Laganà**. The architecture of a Precision Oncology Platform. *Adv Exp Med Biol* 2022; 1361:1-22.
4. **A. Laganà**. Computational Prediction of microRNA Targets. *Adv Exp Med Biol* 2015; 887:231-52.
3. **A. Laganà**, D. Veneziano, F. Russo, A. Pulvirenti, R. Giugno, C. M. Croce, A. Ferro. Computational design of artificial RNA molecules for gene regulation. *Methods Mol Biol* 2015; 1269: 393-412.
2. L. Cascione, A. Ferro, R. Giugno, **A. Laganà**, G. Pigola, A. Pulvirenti, D. Veneziano. Elucidating the Role of microRNAs in Cancer Through Data Mining Techniques. *Adv Exp Med Biol* 2013; 774: 291-315.
1. **A. Laganà**, R. Giugno, A. Pulvirenti, A. Ferro. Computational Approaches to RNAi and Gene Silencing. In *From Linear Operators to Computational Biology: Essays in Memory of Jacob T. Schwartz* 2013; 169-194. Editors: Martin Davis, Edmond Schonberg.

Pre-Prints

5. M. Quidwai, **A. Laganà**. A RAG Chatbot for Precision Medicine of Multiple Myeloma. medRxiv 2024. doi: <https://doi.org/10.1101/2024.03.14.24304293>.
4. P. Restrepo, S. Bhalla, A. Aleman, V. Leshchenko, D.T. Melnekoff, S. Agte, J. Jiang, D. Madduri, J. Richter, S. Richard, A. Chari, H.J. Cho, S. Jagannath, C.J. Walker, Y. Landesman, **A. Laganà**, S. Parekh. A three gene signature predicts response to selinexor in multiple myeloma. medRxiv 2022. doi: <https://doi.org/10.1101/2022.02.25.22271401>.
3. R. Distefano, L. Tomasello, G. L. Rampioni Vinciguerra, P. Gasparini, Y. Xiang, M. Bagnoli, G. P. Marceca, P. Fadda, **A. Laganà**, M. Acunzo, Q. Ma, G. Nigita, C. M. Croce. A concurrent canonical and modified miRNAome pan-cancer study on TCGA and TARGET cohorts leads to an enhanced resolution in cancer. bioRxiv, 2021. doi: <https://doi.org/10.1101/2021.05.18.444694>.
2. S. Bhalla, D. T. Melnekoff, J. Keats, K. Onel, D. Madduri, J. Richter, S. Richard, A. Chari, H. J. Cho, J.T. Dudley, S. Jagannath, **A. Laganà**, S. Parekh. Patient Similarity Network of Multiple Myeloma Identifies Patient Sub-groups with Distinct Genetic and Clinical Features. bioRxiv, 2020. doi: <https://doi.org/10.1101/2020.06.02.129767>.
1. R. N. Tasakis, **A. Laganà**, D. Stamkopolou, D. T. Melnekoff, P. Nedumaran, V. Leshchenko, R. Pecori, S. Parekh, F. Nina Papavasiliou. ADAR1 can drive Multiple Myeloma progression by acting both as an RNA editor of specific transcripts and as a DNA mutator of their cognate genes. bioRxiv 2020. doi: <https://doi.org/10.1101/2020.02.11.943845>. (*Equally contributing authors).

New York (USA), 12/02/2025

A handwritten signature in black ink, appearing to read 'Alessandro Laganà', written in a cursive style.

Alessandro Laganà, PhD